Last reviewed · How we verify
cMAB
cMAB is a monoclonal antibody targeting the PD-1 receptor.
cMAB is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | cMAB |
|---|---|
| Also known as | continuous maximum androgen blockade |
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
cMAB works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and allowing for an enhanced immune response against cancer cells.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
Key clinical trials
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors (PHASE3)
- A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis (PHASE3)
- Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (PHASE2)
- Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (NA)
- A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab (PHASE2)
- CMAB vs IMAB in Metastatic Prostate Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |